Potential partners

You are interested to learn more about our research and products. See this presentation prepared for Bio-Europe 2013 (Vienna, November 4-6) which contains important information about our products available for licensing and financing.

Click on the Full Screen Icon (bottom-right of the video) for a better visual of the presentation. 

Previous partner


In 1979, Dr. Labrie and his team discovered that chronic administration of GnRH agonists in men induces medical castration. GnRH agonists exert an effect equivalent to surgical castration but are more acceptable, thus permitting generalized use, especially in localized prostate cancer where long-term treatment is needed. In 1985, Schering-Plough and Dr. Fernand Labrie signed an agreement for the commercialization of the Combination of GnRH agonists or surgical castration with the antiandrogen Flutamide. The combination of GnRH agonists and Flutamide, also called combined androgen blockade, became the first treatment demonstrated to prolong life in prostate cancer and is now the standard treatment worldwide. Moreover, the data first obtained by Dr. Labrie's team have shown that more than 90% of localized prostate cancers can be cured by combined androgen blockade.

In 1992, EndoResearch signed a collaborative agreement with Schering-Plough for the development of acolbifene against breast cancer.

Schering-Plough Corporation was a United States-based pharmaceutical company. It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. In 1971, the Schering Corporation merged with Plough to form Schering-Plough. On November 4, 2009 Merck & Co. was merged with Schering-Plough with the new company taking the name of Merck & Co.